DNA Nanobots
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
DNA Nanobots is a pre-clinical, precision gene delivery company building targeted non-viral gene therapeutics in a market undergoing a major shift away from viral vectors and lipid nanoparticles. We are developing a new class of gene delivery based on structural control of DNA. Unlike existing systems that are constrained by fixed architectures, Genobots enable programmable, scalable, and repeatable delivery of genetic payloads. We have demonstrated in vivo expression, control over expression patterns, rapid design-driven improvement, scalable payload architectures, and high-dose tolerability. We are now applying this platform through a focused pathfinder program to validate systemic delivery and repeat dosing, while advancing toward our primary objective of full-length dystrophin delivery for Duchenne muscular dystrophy. We are therapeutic-agnostic, but current therapeutic pipeline focuses on novel genetic therapies for Pediatric Muscle, Metabolic, Hematology Disorders and Oncology.
Company HQ City:
Powell
Company HQ State:
Ohio
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
Duchene’s Muscular Dystrophy (DMD)
PEOBLEM: Full-length dystrophin exceeds AAV payload capacity
PROBLEM: Current approaches rely on truncated or partial solutions
SOLUTION: DMD-Genobot enables delivery of large payload (15 kb; full-length dystrophin) with potential for repeat dosing
CEO
James Lynch PhD MBA
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
- DMD
- Factor IX
When you expect your next catalyst update?
August/September 2026
What is your next catalyst (value inflection) update?
In vivo, proof-of-concept of full-length dysdtrophin (DMD-Genobot)
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}